AstraZeneca PLC Fourth quarter and full year results 2011

Thursday, 2 February 2012

David Brennan, Chief Executive Officer said:

Disciplined execution of our strategy has delivered a good performance in 2011 in the face of intensified pricing pressure and generic competition. Our strong cash flow supported a significant increase in cash distributions to shareholders and continued investment to drive future growth and value. While the further expected losses of market exclusivity make for a challenging 2012 outlook, we remain committed to a long-term, focused, R&D based strategy, and today we have announced further steps to drive productivity in all areas to improve returns on our investment in innovation.

Fourth quarter and full year results 2011

Announced on Thursday 2 February 2012

Downloads